Evidence map›Paper›PMID 28293270›Full record

ArticleAIDS research and therapy2017

Effect of

Tsitsi G Monera-Penduka, Charles C Maponga, Alan R Wolfe, Lubbe Wiesner, Gene D Morse, Charles F B Nhachi

Open access · goldAbstract read
In one paragraph

Article in AIDS research and therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
7.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.

  1. Effects ofFrontiers in nutrition · 2025
    Pooled it
  2. Trial
  3. Review
  4. Review
  5. Article
  6. Exploring the Potential ofInternational journal of medical sciences · 2025
    Review
  7. Article
  8. The Hepatoprotective Effects ofPlants (Basel, Switzerland) · 2023
    Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Antioxidant activity and calcium bioaccessibility ofFood science and biotechnology · 2020
    Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 3 countries.

Tsitsi G Monera-Penduka0000 0004 0572 0760grid.13001.33Drug and Toxicology Information Services (DaTIS), School of Pharmacy, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe.
Charles C Maponga0000 0004 0572 0760grid.13001.33Drug and Toxicology Information Services (DaTIS), School of Pharmacy, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe ; 0000 0004 1936 9887grid.273335.3Center for Integrated Global Biomedical Sciences, University at Buffalo, Buffalo, NY USA.
Alan R Wolfe0000 0001 2297 6811grid.266102.1Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA USA.
Lubbe Wiesner0000 0004 1937 1151grid.7836.aDivision of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
Gene D Morse0000 0004 1936 9887grid.273335.3Center for Integrated Global Biomedical Sciences, University at Buffalo, Buffalo, NY USA.
Charles F B Nhachi0000 0004 0572 0760grid.13001.33Department of Clinical Pharmacology, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe.
University of Zimbabwe · ZWUniversity at Buffalo, State University of New York · USUniversity of California, San Francisco · USUniversity of Cape Town · ZA

Funding

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
LOC-IMPAACT Leadership GroupPharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant Women in the USUM1AI068632 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI Jennifer Jao, Sharon A Nachman · 2011 to 2026
$278.1M
Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Marlene Ann Cooper, Michael David Hughes · 2011 to 2026
$246.6M
Validation, CLIA and Qualification (VQC): Enhancing the RS ratio as a tool for AIDS Clinical Trial Group (ACTG) tuberculosis trialsUM1AI106701 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$116.8M
International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) GroupU01AI068632 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI JACKSON, J BROOKS · 2006 to 2010
$109.7M
University of Buffalo Clinical and Translational Science Institute - Supplement SchulyerUL1TR001412 · NCATS · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI MURPHY, TIMOTHY F · 2015 to 2024
$33.8M
African Training Program for Research in AIDS & TBU2RTW007367 · FIC · BIOMEDICAL RESEARCH &TRAINING INSTITUTE · PI MASON, PETER ROBERT · 2005 to 2014
$4.8M
HIV Research Training ProgramD43TW010313 · FIC · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI Charles Enos Chiedza Maponga, Gene D. Morse · 2016 to 2026
$3.2M
Antiretroviral Pharmacology Training in Resource Poor CountriesD43TW007991 · FIC · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI MORSE, GENE D. · 2009 to 2015
$1.6M
FIC NIH HHS D43 TW007991FIC NIH HHS D43 TW010313FIC NIH HHS U2R TW007367NCATS NIH HHS UL1 TR001412NIAID NIH HHS U01 AI068632NIAID NIH HHS UM1 AI068632NIAID NIH HHS UM1 AI068634NIAID NIH HHS UM1 AI068636NIAID NIH HHS UM1 AI106701
6 · The paper itself

Abstract

background

methodsAdult patients at steady-state dosing with nevirapine were admitted for 12-h intensive PK sampling following a 21-day herbal medicine washout. Blood sampling was repeated after 14 days of nevirapine and moringa (1.85 g leaf powder/day) co-administration. Nevirapine plasma concentrations were determined by liquid chromatography-tandem mass spectrometry. To assess the effect of moringa on nevirapine PK, the change in nevirapine area under the plasma concentration-time curve (AUC) was determined. The mean difference in pre- and post-moringa nevirapine, maximum concentration (C

resultsPharmacokinetics analyses were performed on the results from 11 participants for whom complete data were obtained. The post/pre GMRs and associated 90% CIs for nevirapine were 1.07 (1.00-1.14) for the AUC; 1.06 (0.98-1.16) for C

conclusionCo-administration of

Indexed as

Drug InteractionsAdultAgedAnti-HIV AgentsChromatography, LiquidCross-Over StudiesFemaleHIV InfectionsHumansMaleMass SpectrometryMiddle AgedMoringa oleiferaNevirapinePlant LeavesPlasmaAnti-HIV AgentsNevirapinePowdersHIVMoringa oleiferaNevirapinePharmacokinetics

Identifiers

PMID28293270
PMCPMC5348890
OpenAlexW2595103918

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.